S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle

Relay Therapeutics (RLAY) Stock Forecast, Price & News

$8.41
+0.17 (+2.06%)
(As of 09/29/2023 ET)
Compare
Today's Range
$8.16
$8.55
50-Day Range
$8.24
$12.60
52-Week Range
$7.82
$24.17
Volume
882,617 shs
Average Volume
1.12 million shs
Market Capitalization
$1.03 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.06

Relay Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
209.8% Upside
$26.06 Price Target
Short Interest
Bearish
23.71% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.16mentions of Relay Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$43,825 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.28) to ($3.56) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.56 out of 5 stars

Medical Sector

895th out of 972 stocks

Biological Products, Except Diagnostic Industry

145th out of 155 stocks


RLAY stock logo

About Relay Therapeutics (NASDAQ:RLAY) Stock

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and GDC-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

RLAY Price History

RLAY Stock News Headlines

Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
U.S. "Shadow Banks" About to Blow up again?
Analyst who called Lehman crash says our biggest calamities (1907, 1929, 2007, etc) all start in the same spot--and it’s about to happen again. More here.
Barclays Sticks to Its Hold Rating for Relay Therapeutics (RLAY)
What 11 Analyst Ratings Have To Say About Relay Therapeutics
See More Headlines
Receive RLAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Relay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RLAY Company Calendar

Last Earnings
8/08/2023
Today
10/01/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RLAY
Fax
N/A
Employees
345
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$26.06
High Stock Price Forecast
$34.00
Low Stock Price Forecast
$12.50
Forecasted Upside/Downside
+209.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Net Income
$-290,510,000.00
Net Margins
-36,562.53%
Pretax Margin
-36,562.53%

Debt

Sales & Book Value

Annual Sales
$1.38 million
Book Value
$7.86 per share

Miscellaneous

Free Float
117,810,000
Market Cap
$1.03 billion
Optionable
Not Optionable
Beta
1.38
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Alexis A. Borisy A.M. (Age 51)
    Co-Founder & Independent Chairman
    Comp: $85k
  • Dr. Sanjiv K. Patel M.A. (Age 49)
    M.B.A., M.D., MBBS, CEO, Pres & Director
    Comp: $1.03M
  • Dr. Mark Murcko Ph.D. (Age 63)
    Co-Founder & Director
    Comp: $50k
  • Mr. Thomas  CatinazzoMr. Thomas Catinazzo (Age 46)
    Chief Financial Officer
    Comp: $599.83k
  • Mr. Brian R. Adams J.D. (Age 49)
    Chief Legal Officer & Sec.
    Comp: $598.53k
  • Dr. Donald A. Bergstrom M.D.Dr. Donald A. Bergstrom M.D. (Age 51)
    Ph.D., Pres of R&D
    Comp: $711.25k
  • Mr. Peter Rahmer
    Chief Corp. Devel. Officer
  • Dr. Deborah Palestrant Ph.D.
    VP of Corp. Devel. & Strategy
  • Mr. Jim Watters Ph.D.
    Chief Scientific Officer of Late Research
  • Dr. Beni B. Wolf M.D.
    Ph.D., Chief Medical Officer & Head of Precision Medicine













RLAY Stock - Frequently Asked Questions

Should I buy or sell Relay Therapeutics stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Relay Therapeutics in the last twelve months. There are currently 2 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RLAY shares.
View RLAY analyst ratings
or view top-rated stocks.

What is Relay Therapeutics' stock price forecast for 2023?

10 brokerages have issued 12-month target prices for Relay Therapeutics' stock. Their RLAY share price forecasts range from $12.50 to $34.00. On average, they expect the company's stock price to reach $26.06 in the next twelve months. This suggests a possible upside of 209.8% from the stock's current price.
View analysts price targets for RLAY
or view top-rated stocks among Wall Street analysts.

How have RLAY shares performed in 2023?

Relay Therapeutics' stock was trading at $14.94 on January 1st, 2023. Since then, RLAY shares have decreased by 43.7% and is now trading at $8.41.
View the best growth stocks for 2023 here
.

When is Relay Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our RLAY earnings forecast
.

How were Relay Therapeutics' earnings last quarter?

Relay Therapeutics, Inc. (NASDAQ:RLAY) posted its earnings results on Tuesday, August, 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by $0.03. The firm had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.81 million. Relay Therapeutics had a negative net margin of 36,562.53% and a negative trailing twelve-month return on equity of 37.81%. The firm's revenue for the quarter was down 67.4% on a year-over-year basis. During the same period in the prior year, the business posted ($0.71) earnings per share.

What ETFs hold Relay Therapeutics' stock?

ETFs with the largest weight of Relay Therapeutics (NASDAQ:RLAY) stock in their portfolio include TrueShares Technology, AI & Deep Learning ETF (LRNZ), Range Cancer Therapeutics ETF (CNCR) and SPDR S&P Biotech ETF (XBI).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of Relay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Relay Therapeutics investors own include Beyond Meat (BYND), CureVac (CVAC), QuidelOrtho (QDEL), Teladoc Health (TDOC), Tesla (TSLA), Datadog (DDOG), DraftKings (DKNG), eHealth (EHTH), GoHealth (GOCO) and Intel (INTC).

When did Relay Therapeutics IPO?

(RLAY) raised $250 million in an initial public offering (IPO) on Thursday, July 16th 2020. The company issued 14,700,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs, Cowen and Guggenheim Securities acted as the underwriters for the IPO.

What is Relay Therapeutics' stock symbol?

Relay Therapeutics trades on the NASDAQ under the ticker symbol "RLAY."

How do I buy shares of Relay Therapeutics?

Shares of RLAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Relay Therapeutics' stock price today?

One share of RLAY stock can currently be purchased for approximately $8.41.

How much money does Relay Therapeutics make?

Relay Therapeutics (NASDAQ:RLAY) has a market capitalization of $1.03 billion and generates $1.38 million in revenue each year. The company earns $-290,510,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis.

How many employees does Relay Therapeutics have?

The company employs 345 workers across the globe.

How can I contact Relay Therapeutics?

Relay Therapeutics' mailing address is 399 BINNEY STREET 2ND FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.relaytx.com. The company can be reached via phone at 617-370-8837 or via email at prahmer@relaytx.com.

This page (NASDAQ:RLAY) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -